Invest Puerto Rico Case Studies
CytoImmune Therapeutics Puerto Rico Core business: Development of cell therapy which utilizes a patient’s own immune system to treat cancer, the first cell therapy development in Puerto Rico. Signature product: CytoImmune currently develops natural killer (NK) cell immunotherapy that involves a CAR NK cell. There is potential to use NK cells to create off-the-shelf cell therapies that are safe and effective in a wide range of cancers, including solid tumors. This technology enables the cell to recognize specific proteins or antigens present on the surface of tumor cells. Location: A 37,000 sq. ft. facility in Toa Baja, a municipality on the Island’s north coast. Investment: $28 million in machinery and equipment. Economic impact: 100 direct jobs with an estimated total payroll of $7 million per year. Business footprint: With over 570 publications and many patents between them, company founders have achieved many firsts in human NK cell development, survival, activation, in vivo modulation, and preclinical models of human NK CAR therapy cancer. The Company has completed its first phase of manufacturing and is able to make up to 4000 doses per year.
“Puerto Rico was the obvious choice for expanding our operations. The Island, with its proven history in the life science sector, has what it takes to support our research and development, including a deep talent pool, supportive business climate and many other high-value intangibles.” Will Rosellini, Co-Founder and President of CytoImmune.
22
INVEST PUERTO RICO • ANNUAL REPORT 2021
